

# Margaret L Macmillan

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2756324/margaret-l-macmillan-publications-by-citations.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

119  
papers

4,748  
citations

33  
h-index

68  
g-index

127  
ext. papers

5,432  
ext. citations

3.3  
avg, IF

4.99  
L-index

#	Paper	IF	Citations
119	Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. <i>Blood</i> , <b>2002</b> , 100, 1611-8	2.2	870
118	Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. <i>Biology of Blood and Marrow Transplantation</i> , <b>2002</b> , 8, 387-94	4.7	310
117	Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. <i>Blood</i> , <b>2009</b> , 114, 4293-9	2.2	251
116	Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. <i>Blood</i> , <b>2016</b> , 127, 1044-51	2.2	251
115	Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. <i>Blood</i> , <b>2009</b> , 113, 2410-5	2.2	171
114	Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. <i>Blood</i> , <b>2004</b> , 104, 1559-64	2.2	170
113	Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia. <i>Blood</i> , <b>2007</b> , 109, 2256-62	2.2	162
112	Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia. <i>Blood</i> , <b>2004</b> , 103, 3226-9	2.2	158
111	Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. <i>Blood</i> , <b>2014</b> , 124, 1372-7	2.2	142
110	A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 761-7	4.7	132
109	Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2002</b> , 8, 40-6	4.7	120
108	Successful hematopoietic stem cell transplantation for Fanconi anemia from an unaffected HLA-genotype-identical sibling selected using preimplantation genetic diagnosis. <i>Blood</i> , <b>2004</b> , 103, 1147-51	2.2	111
107	The best endpoint for acute GVHD treatment trials. <i>Blood</i> , <b>2010</b> , 115, 5412-7	2.2	110
106	Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a	14.6	101
105	Haematopoietic cell transplantation for Fanconi anaemia: when and how?. <i>British Journal of Haematology</i> , <b>2010</b> , 149, 14-21	4.5	97
104	Twenty years of unrelated donor bone marrow transplantation for pediatric acute leukemia facilitated by the National Marrow Donor Program. <i>Biology of Blood and Marrow Transplantation</i> , <b>2008</b> , 14, 16-22	4.7	82
103	A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. <i>Blood</i> , <b>2007</b> , 109, 2657-62	2.2	74

102	Diagnosis of myelodysplastic syndrome among a cohort of 119 patients with fanconi anemia: morphologic and cytogenetic characteristics. <i>American Journal of Clinical Pathology</i> , <b>2010</b> , 133, 92-100	1.9	73
101	Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. <i>Blood</i> , <b>2014</b> , 124, 3221-7; quiz 3335	2.2	72
100	Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation. <i>Pediatric Blood and Cancer</i> , <b>2006</b> , 46, 630-6	3	72
99	What predicts high risk acute graft-versus-host disease (GVHD) at onset?: identification of those at highest risk by a novel acute GVHD risk score. <i>British Journal of Haematology</i> , <b>2012</b> , 157, 732-41	4.5	69
98	Alternative donor hematopoietic cell transplantation for Fanconi anemia. <i>Blood</i> , <b>2015</b> , 125, 3798-804	2.2	67
97	Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy. <i>American Journal of Medicine</i> , <b>2002</b> , 112, 369-79	2.4	58
96	Allogeneic hematopoietic cell transplantation for fanconi anemia in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome, or acute leukemia. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1669-76	2.2	56
95	Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 1636-1645	4.7	56
94	Hematopoietic cell transplantation in Fanconi anemia: current evidence, challenges and recommendations. <i>Expert Review of Hematology</i> , <b>2017</b> , 10, 81-97	2.8	52
93	Risk Factors for Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Matched Sibling Donors. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 134-40	4.7	52
92	Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement. <i>Biology of Blood and Marrow Transplantation</i> , <b>2009</b> , 15, 777-84	4.7	52
91	Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 1029-36	4.7	49
90	Costs of pediatric allogeneic hematopoietic-cell transplantation. <i>Pediatric Blood and Cancer</i> , <b>2010</b> , 54, 138-43	3	43
89	Haematopoietic cell transplantation for acute leukaemia and advanced myelodysplastic syndrome in Fanconi anaemia. <i>British Journal of Haematology</i> , <b>2014</b> , 164, 384-95	4.5	41
88	High-producer interleukin-2 genotype increases risk for acute graft-versus-host disease after unrelated donor bone marrow transplantation. <i>Transplantation</i> , <b>2003</b> , 76, 1758-62	1.8	38
87	Interleukin-1 genotype and outcome of unrelated donor bone marrow transplantation. <i>British Journal of Haematology</i> , <b>2003</b> , 121, 597-604	4.5	38
86	Higher Dose of Mycophenolate Mofetil Reduces Acute Graft-versus-Host Disease in Reduced-Intensity Conditioning Double Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 926-33	4.7	33
85	Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. <i>Blood</i> , <b>2020</b> , 135, 97-107	2.2	29

84	Management of acute graft-versus-host disease in children. <i>Pediatric Clinics of North America</i> , <b>2010</b> , 57, 273-95	3.6	28
83	Patient interleukin-18 GCG haplotype associates with improved survival and decreased transplant-related mortality after unrelated-donor bone marrow transplantation. <i>British Journal of Haematology</i> , <b>2004</b> , 126, 704-10	4.5	28
82	Outcomes and Predictors of Response in Steroid-Refractory Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 2297-2302	4.7	20
81	Cellular therapy for fanconi anemia: the past, present, and future. <i>Biology of Blood and Marrow Transplantation</i> , <b>2011</b> , 17, S109-14	4.7	19
80	Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults. <i>Haematologica</i> , <b>2016</b> , 101, 764-72	6.6	19
79	Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 521-528	4.7	19
78	Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 2025-2030	4.7	18
77	Comparable Outcomes after HLA-Matched Sibling and Alternative Donor Hematopoietic Cell Transplantation for Children with Fanconi Anemia and Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 765-771	4.7	18
76	Transplant outcomes in bone marrow failure syndromes and hemoglobinopathies. <i>Seminars in Hematology</i> , <b>2010</b> , 47, 37-45	4	17
75	CRISPR/Cas9 Targeted Gene Editing and Cellular Engineering in Fanconi Anemia. <i>Stem Cells and Development</i> , <b>2016</b> , 25, 1591-1603	4.4	16
74	Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802. <i>Blood Advances</i> , <b>2018</b> , 2, 1882-1888	7.8	16
73	Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 879-83	4.7	15
72	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1459-1468	4.7	14
71	Bone mineral density in children with fanconi anemia after hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 894-9	4.7	12
70	Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by NF1 deficiency. <i>Haematologica</i> , <b>2016</b> , 101, 1190-1199	6.6	12
69	Interleukin-1 alpha genotype and outcome of unrelated donor haematopoietic stem cell transplantation for chronic myeloid leukaemia. <i>British Journal of Haematology</i> , <b>2007</b> , 137, 152-7	4.5	12
68	Pulmonary Complications in Pediatric and Adolescent Patients Following Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 2024-2030	4.7	11
67	First phase insulin release and glucose tolerance in children with Fanconi anemia after hematopoietic cell transplantation. <i>Pediatric Blood and Cancer</i> , <b>2009</b> , 53, 191-6	3	10

66	Pediatric acute GVHD: clinical phenotype and response to upfront steroids. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 165-171	4.4	10
65	Facilitating resolution of life-threatening acute GVHD with human chorionic gonadotropin and epidermal growth factor. <i>Blood Advances</i> , <b>2020</b> , 4, 1284-1295	7.8	10
64	Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 825-33	4.7	9
63	Endocrinopathies, Bone Health, and Insulin Resistance in Patients with Fanconi Anemia after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 1487-1492	4.7	9
62	Hematopoietic Stem Cell Transplantation for Shwachman-Diamond Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1446-1451	4.7	9
61	First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings. <i>Blood Advances</i> , <b>2021</b> , 5, 1425-1436	7.8	9
60	Diffuse alveolar hemorrhage is most often fatal and is affected by graft source, conditioning regimen toxicity, and engraftment kinetics. <i>Haematologica</i> , <b>2018</b> , 103, 2109-2115	6.6	9
59	Fanconi anemia: correlating central nervous system malformations and genetic complementation groups. <i>Pediatric Radiology</i> , <b>2017</b> , 47, 868-876	2.8	8
58	Validation of Minnesota acute graft--host disease Risk Score. <i>Haematologica</i> , <b>2020</b> , 105, 519-524	6.6	8
57	Growth hormone treatment of patients with Fanconi anemia after hematopoietic cell transplantation. <i>Pediatric Blood and Cancer</i> , <b>2014</b> , 61, 1142-3	3	8
56	Hematopoietic cell transplantation for congenital bone marrow failure. <i>Current Opinion in Oncology</i> , <b>2005</b> , 17, 106-13	4.2	8
55	Comparison of total body irradiation non-total body irradiation containing regimens for de novo acute myeloid leukemia in children. <i>Haematologica</i> , <b>2021</b> , 106, 1839-1845	6.6	7
54	Pretransplant Serum Citrulline Predicts Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 2190-2196	4.7	7
53	Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-Up. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 56-62	4.7	7
52	Stress responses, M2 macrophages, and a distinct microbial signature in fatal intestinal acute graft-versus-host disease. <i>JCI Insight</i> , <b>2019</b> , 5,	9.9	6
51	Paternal or Maternal Uniparental Disomy of Chromosome 16 Resulting in Homozygosity of a Mutant Allele Causes Fanconi Anemia. <i>Human Mutation</i> , <b>2016</b> , 37, 465-8	4.7	6
50	Thymic Shielding (TS) in Recipients of Total Body Irradiation (TBI) and Alternative Donor Hematopoietic Stem Cell Transplant (AD-HSCT): Reduced Risk of Opportunistic Infection in Patients with Fanconi Anemia (FA).. <i>Blood</i> , <b>2006</b> , 108, 3134-3134	2.2	5
49	Amphiregulin in intestinal acute graft-versus-host disease: a possible diagnostic and prognostic aid. <i>Modern Pathology</i> , <b>2019</b> , 32, 560-567	9.8	5

48	Broad-Spectrum Antibiotics and Risk of Graft-versus-Host Disease in Pediatric Patients Undergoing Transplantation for Acute Leukemia: Association of Carbapenem Use with the Risk of Acute Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 177.e1-177.e8	5
47	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 642-649	4
46	Upper gastrointestinal acute graft-host disease adds minimal prognostic value in isolation or with other graft-host disease symptoms as currently diagnosed and treated. <i>Haematologica</i> , <b>2018</b> , 103, 1708-1719	6.6 3
45	Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia. <i>Haematologica</i> , <b>2020</b> , Online ahead of print,	6.6 3
44	High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 96	7 3
43	Elevations in serum alpha fetoprotein levels in patients with Fanconi anaemia. <i>British Journal of Haematology</i> , <b>2019</b> , 184, 1032-1035	4.5 3
42	Dynamic Graft-versus-Host Disease-Free, Relapse-Free Survival: Multistate Modeling of the Morbidity and Mortality of Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 1884-1889	4.7 2
41	Plasma Short Chain Fatty Acids As a Predictor of Response to Therapy for Life-Threatening Acute Graft-Versus-Host Disease. <i>Blood</i> , <b>2020</b> , 136, 14-14	2.2 2
40	Chronic Graft Versus Host Disease (cGVHD) Following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate in Recipients of Unrelated Donor (URD) Umbilical Cord Blood (UCB).. <i>Blood</i> , <b>2005</b> , 106, 1814-1814	2.2 2
39	Dyskeratosis Congenita: Low Regimen-Related Toxicity Following Hematopoietic Cell Transplantation (HCT) Using a Reduced Intensity Conditioning Regimen.. <i>Blood</i> , <b>2007</b> , 110, 2005-2005	2.2 2
38	New Classification of Chronic Graft Versus Host Disease: Added Clarity from the Consensus Diagnoses.. <i>Blood</i> , <b>2007</b> , 110, 41-41	2.2 2
37	Steroid-dependent acute GVHD after allogeneic hematopoietic cell transplantation: risk factors and clinical outcomes. <i>Blood Advances</i> , <b>2021</b> , 5, 1352-1359	7.8 2
36	Outcomes of chronic graft-versus-host disease following matched sibling donor versus umbilical cord blood transplant. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 1373-1380	4.4 2
35	Phenotypic variability in patients with Fanconi anemia and biallelic FANCF mutations. <i>American Journal of Medical Genetics, Part A</i> , <b>2017</b> , 173, 260-263	2.5 1
34	First-in-Human Clinical Trial to Determine the Safety and Potency of Inducible T Regulatory Cells after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , <b>2018</b> , 132, 2112-2112	2.2 1
33	Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A Phase I Study. <i>Blood</i> , <b>2018</b> , 132, 71-71	2.2 1
32	Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> ,	1
31	Guidelines for the Prevention and Management of Graft-versus-Host Disease after Cord Blood Transplantation. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 540-544	1

30	Hematopoietic Cell Transplantation for Fanconi Anemia <b>2016</b> , 923-946		1
29	A Review of Infections After Hematopoietic Cell Transplantation Requiring PICU Care: Transplant Timeline Is Key. <i>Frontiers in Pediatrics</i> , <b>2021</b> , 9, 634449	3.4	1
28	Elevated AREG/EGF Ratio Prior to Transplantation Is Associated with Pre-Transplant Clostridium Difficile Infection, Unresolved Tissue Damage, and Poorer Overall Survival. <i>Blood</i> , <b>2018</b> , 132, 3353-3353	2.2	0
27	Multiply restimulated human thymic regulatory T cells express distinct signature regulatory T-cell transcription factors without evidence of exhaustion. <i>Cytotherapy</i> , <b>2021</b> , 23, 704-714	4.8	0
26	Low 5-year health care burden after umbilical cord blood transplantation. <i>Blood Advances</i> , <b>2021</b> , 5, 853-868		0
25	Late-Onset Acute and Chronic Graft-versus-Host Disease in Children: Clinical Features and Response to Therapy. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 667.e1-667.e5		0
24	Detection and treatment of cerebral toxoplasmosis in an aplastic pediatric post-allogeneic hematopoietic cell transplant patient: a case report. <i>BMC Infectious Diseases</i> , <b>2021</b> , 21, 941	4	0
23	High Incidence of Venous Thromboembolism in Patients with Chronic Graft-Versus-Host Disease. <i>Blood</i> , <b>2020</b> , 136, 44-46	2.2	
22	Predictors and Outcomes of Flares in Chronic Graft-Versus-Host Disease. <i>Blood</i> , <b>2020</b> , 136, 47-48	2.2	
21	Bacterial Prophylaxis in Patients with Acute Gvhd; Who Is at Risk for Bloodstream Infections?. <i>Blood</i> , <b>2021</b> , 138, 2870-2870	2.2	
20	Low Incidence of Chronic Graft-Versus-Host Disease in Myeloablative Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Using Matched Related or Unrelated Donors: Phase II Study Interim Analysis. <i>Blood</i> , <b>2021</b> , 138, 1811-1811	2.2	
19	Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD. <i>Bone Marrow Transplantation</i> , <b>2021</b> ,	4.4	
18	Reduced Intensity Compared to High Dose Conditioning for Allotransplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Comparative Clinical Analysis.. <i>Blood</i> , <b>2004</b> , 104, 1817-1817	2.2	
17	Acute Graft-Versus-Host Disease: Clinical Presentation and Response to Therapy Following Umbilical Cord Blood Transplant.. <i>Blood</i> , <b>2004</b> , 104, 2148-2148	2.2	
16	Fludarabine Is Superior to Cladribine When Added to Busulfan and Low Dose TBI as Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT): A Prospective Randomized Trial.. <i>Blood</i> , <b>2004</b> , 104, 1825-1825	2.2	
15	Interleukin-1 Genotype and Outcome of Unrelated Donor BMT for CML.. <i>Blood</i> , <b>2005</b> , 106, 2057-2057	2.2	
14	Myelodysplastic Syndrome in Fanconi Anemia: Morphologic and Cytogenetic Findings Are Strongly Correlated.. <i>Blood</i> , <b>2007</b> , 110, 2458-2458	2.2	
13	5 Year Health Care Burden after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): Impact of Graft Source. <i>Blood</i> , <b>2018</b> , 132, 367-367	2.2	

12	Validation of Minnesota Acute GVHD Risk Score and Identification of New Factors Associated with Initial Response to Steroids: Not All GVHD Is Created Equal. <i>Blood</i> , <b>2018</b> , 132, 67-67	2.2
11	Pre-Transplant Serum Claudin-3 Predicts Intestinal Graft-Versus-Host Disease and Non-Relapse Mortality Risk after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , <b>2019</b> , 134, 39-39	2.2
10	Early Broad-Spectrum Antibiotics and Risk of Acute Graft-Versus-Host Disease in Children: An Analysis from the Center for International Blood and Marrow Transplantation Research (CIBMTR) and the Pediatric Health Information System (PHIS). <i>Blood</i> , <b>2019</b> , 134, 599-599	2.2
9	Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT). <i>Blood</i> , <b>2019</b> , 134, 2009-2009	2.2
8	What Predicts High Risk Acute Gvhd At Diagnosis?: Identification of Those At Highest Risk by a Novel Acute Gvhd Risk Score,. <i>Blood</i> , <b>2011</b> , 118, 4062-4062	2.2
7	Hematopoietic Cell Transplantation for FA Patients with Acute Leukemia or Advanced MDS,. <i>Blood</i> , <b>2011</b> , 118, 4146-4146	2.2
6	Elevated Absolute Lymphocyte Counts Following Acute Graft Vs. Host Disease Treatment Is Associated with Therapeutic Responses and Lower Non-Relapse Mortality Following Umbilical Cord Blood Transplant,. <i>Blood</i> , <b>2011</b> , 118, 4085-4085	2.2
5	Increased Relapse Associated with Mixed Donor-Donor Chimerism Following Double Umbilical Cord Blood Transplantation (dUCBT). <i>Blood</i> , <b>2012</b> , 120, 358-358	2.2
4	Allele Level HLA Matching On Outcomes After Double Umbilical Cord Blood (dUCB) Transplantation for Hematological Malignancies: Stronger Graft Vs. Leukemia with HLA Mismatch. <i>Blood</i> , <b>2012</b> , 120, 1976-1976	2.2
3	Shotgun sequencing of the faecal microbiome to predict response to steroids in patients with lower gastrointestinal acute graft-versus-host disease: An exploratory analysis. <i>British Journal of Haematology</i> , <b>2021</b> , 192, e69-e73	4.5
2	Weight-based mycophenolate mofetil dosing predicts acute GVHD and relapse after allogeneic hematopoietic cell transplantation. <i>European Journal of Haematology</i> , <b>2021</b> , 106, 205-212	3.8
1	Hematopoietic Cell Transplantation for Fanconi's Anemia 1178-1199	